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Reply to Croes et al.
To the Editor:
Croes et al. (2000 [in this issue]) make the point that
genetic testing as a diagnostic tool shows poor per-
formance in differential diagnosis in general medical
practice. We fully agree with this comment. Therefore,
one of the goals of our study (Finckh et al. 2000) was
to establish criteria that would increase the chance of
identifying a pathogenic mutation in the setting of a
specialized clinic. Indeed, among patients who had
both onset at an early age and positive family history
for early-onset dementia (EOD), diagnostic sequenc-
ing identified disease-relevant mutations in 150% of
the patients analyzed by us. Another notable result of
our study was the finding of four prion mutations
among the 36 EOD patients, which suggested that
atypical forms of prion disease may remain underdi-
agnosed. This assumption is supported by indepen-
dent observations, such as those made by two coau-
thors of the letter by Croes et al. (2000), who found
a PRNP insertion mutation in a patient with both
prion disease and ante mortem diagnosis of familial
Alzheimer disease (FAD) (Dermaut et al. 1998).
We agree with Croes et al. that assessment of the
relevance of previously unknown mutations is a dif-
ficult issue. Nonetheless, in recent screening studies
of FAD, 72%–83% of the sequence changes corre-
sponded to pathogenic mutations already reported
(Kamimura et al. 1998; Campion et al. 1999). In our
study, 58% of the mutations had been previously de-
scribed by others. Repeated identification of any given
rare mutation in a rare disorder, together with the
absence of the mutation in control probands, signif-
icantly increases the likelihood that it has causative
effects.
We were pleased to see that Croes et al. agree with
our conclusion that E318G in PS1 is a nonpathogenic
polymorphism and that they reemphasize the impor-
tance of a careful and critical analysis of the literature.
The importance of early and disease-specific diagnosis
of EOD as a way of identifying treatable forms of
dementia is an issue separate from our assertion that
diagnostic sequencing of the four known EOD genes
may provide important information for proper clinical
and genetic counseling in the early phases of the
disorder.
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The Efficiency of Pooling in the Detection of Rare
Mutations
To the Editor:
After citing a variety of uses of pooled testing in ge-
netic studies, Amos et al. (2000) suggested that mu-
tations in individual patients could be detected more
efficiently by being tested in pools. A typical muta-
tion-detection protocol requires that many segments
of the gene—for example, an amplicon consisting of
one or a few close exons—need to be evaluated for
detection of a mutation. Thus, even if the mutation
has a prevalence of ∼2%, as in the case of BRCA1 or
BRCA2 in Ashkenazim (Hartge et al. 1999), the prob-
ability that any segment will contain a mutation is
much smaller, perhaps on the order of .0005–.005.
The use of pools or groups of samples to identify
individuals or to estimate the prevalence of such a
rare characteristic has been extensively studied in the
statistical literature (Dorfman 1943; Sobel and Elash-
off 1972; Gastwirth and Hammick 1989; Tu et al.
1995; Brookmeyer 1999). Using the corrected formula
(see the erratum by Amos et al. [in this issue]) for the
number of runs or tests needed to identify individuals
with a mutation, one can fully appreciate the potential
of pooling methods. A variant of the grouping pro-
cedure is described that in some circumstances leads
to greater gains in efficiency when grouped testing is
utilized.
The sensitivity of an assay—that is, the probability
that a mutation will be detected, given that at least
one member of the pool has it—is a potential limiting
factor in practice. For screening of individuals to de-
termine their carrier status, the sensitivity should be
as close as possible to 100%. For detection of mu-
tations by multiplex single-nucleotide primer exten-
sion, 100% sensitivity was achieved in pools of size
10–20 but dropped to 80% in pools of 30 (Krook et
al. 1992). When denaturing high-performance liquid
chromatography was used to identify BRCA muta-
tions, 100% sensitivity was observed for several am-
plicons studied in groups of size five to nine (J. Rutter,
personal communication). Thus, for the largest pool
size for which a mutation detector is 100% sensitive,
it is helpful to know the largest mutation prevalence
for which pooling is efficient.
Suppose that the prevalence of a mutation in a sin-
gle unit (exon or amplicon) being studied is p and
that n individuals donate samples. For pools of size
r, the probability, g, that at least one member of the
pool has a mutation is . Assume that ther1 (1 p)
test is 100% accurate in classifying a pool as having
or not having a mutation. Since Y, the number of runs
or tests that need to be done without pooling is n, for
any pooling protocol in which the ratio of the ex-
pected value (y) of , the strategy saves runs.Y:n ! 1
We denote this ratio by F, for fraction of tests required
relative to individual testing; and the efficiency of a
pooling method is , the fraction of tests saved.1 F
When the classical single-stage pooling method (Dorf-
man 1943), which retests, one at a time, the individ-
uals in a positive pool, is used, the expected number
of runs needed to completely identify all the mutations
in the segment under study in the sample of n indi-
viduals is
n
E(Y)p  ng . (1)( )r
The derivation follows. The probability that a pool
contains a mutation, which implies that it will test
positive, is g. Since all r individuals in the pool will
be tested, a positive pool receives a total of tests.r 1
The probability that a pool is negative is ( ).1 g
Those pools are classified with one test, so the ex-
pected number of tests per pool is (r 1)g (1
. Since there are pools, the expectedng)p 1 gr r
number of tests is given by equation (1). Note that
the prevalence, p, enters into equation (1) because it
determines the probability, g, that a pool is positive.
Amos et al. (2000) also considered the situation in
which there is a probability b, of a false-positive result
in a pool—that is, is the specificity of the mu-1 b
tation-detection process while the sensitivity remains
perfect. The same reasoning that led to equation (1)
shows that the expected number, y, of runs or tests is
given by
1 ryp n  [1 (1 b)(1  p) ] . (2){ }r
From equations (1) and (2), we can calculate the
range of values of p for which the ratio of the expected
number, y, of tests or runs (Y) to the total sample size,
n, is !1, which implies that pooling is at least as ef-
ficient as individual testing. We also present the largest
p value, p.5, for which , which indicates that
y ! .5n
pooling will result in a substantial savings in the ex-
